Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$365.00K$365.00K−56.8% vs Q2 2021 Net Income-$76.79M-$76.79MN/M vs Q2 2021 EPS Diluted-$0.71-$0.71N/M vs Q2 2021 Operating Income-$77,811,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$58,950,000N/M Margins · derivedOperating margin-21318.1%+1617.9 pt vs Q2 2021
Net margin-21037.8%+1876.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end